Columbia neurologist William Kreisl, MD, explains the potential uses—and limitations—of a smell test in sniffing out Alzheimer’s disease risk.
Clinical trial shows that solanezumab, an antibody-based treatment for Alzheimer’s disease, does not significantly slow cognitive decline.
Researchers at Columbia University found that dementia is on the decline in seniors from northern Manhattan, following national trends.
A new study suggests a smell test can identify people with mild cognitive impairment–often a precursor to Alzheimer’s–who may benefit from cholinesterase inhibitors.
Scientists propose a new model for Alzheimer's disease that may explain the high failure rate of recent clinical trials.
Memories "lost" to Alzheimer's disease may just be hard to retrieve, suggests a new study by neuroscientists at Columbia University Medical Center.